Merck (MRK) tops earnings, revenue expectations but guidance mixed

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. IBM
2. PRIM
3. META
4. ABBV
5. NAVN
6. CNC
7. KFY
8. MU
9. DPZ
10. PLTR

Go back to Merck (MRK) tops earnings, revenue expectations but guidance mixed

Merck Announces Second-Quarter 2024 Financial Results

July 30, 2024 6:30 AM EDT

Total Worldwide Sales Were $16.1 Billion, an Increase of 7% From Second Quarter 2023; Excluding the Impact of Foreign Exchange, Growth Was 11% KEYTRUDA Sales Grew 16% to $7.3 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 21% GAAP EPS Was $2.14; Non-GAAP EPS Was $2.28 Successful Initial Launch of WINREVAIR in the U.S.; Received Positive EU CHMP Opinion for Adults With PAH Achieved Key Milestones in Vaccine Programs Following FDA Approval, CAPVAXIVE Unanimously Recommended by the CDCs ACIP for Pneumococcal Vaccination for Certain Adults Announced Positive Results From Phase 2b/3 Trial of Clesrovimab (MK-1654),... More

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma

July 26, 2024 6:50 AM EDT

Opinion granted based on positive overall survival and progression-free survival results from the Phase 3 KEYNOTE-A39 trial

Positive opinion marks step forward for a potential new first-line standard of care for the treatment of patients with this disease in... More